(6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
[CAS# 2477812-39-6]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound >> Alcohol
• Name: (6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
• Molecular Formula: C₁₇H₁₉NO₂
• Molecular Weight: 269.34
• CAS Registry Number: 2477812-39-6
• SMILES: COC1=CC(=C(C=C1)[C@@H]2CCC3=C(C2)C=CC(=C3)O)N

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H315-H319
• Safety Statements: P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Discovery and Applications

(6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol is a synthetic compound that is of great interest in pharmaceutical research due to its unique chemical structure and potential therapeutic applications. (6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol was originally synthesized with the goal of developing new pharmacologically active molecules. Researchers aimed to explore the potential of tetrahydronaphthalene derivatives because their structures are similar to naturally occurring bioactive molecules. Through targeted synthetic strategies, including asymmetric synthesis, the (6R)-enantiomer was isolated and its promising biological activities were identified.

The compound has a molecular formula of C17H19NO2 and has a tetrahydronaphthalene core, a structure that confers it with remarkable rigidity and stability. The amino and methoxy groups on the benzene ring enhance its potential for various interactions with biological targets. Its stereochemistry, especially the (6R)-configuration, plays a crucial role in its binding affinity and selectivity for specific receptors or enzymes.

The main application of (6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol is in drug development. Its structure allows it to mimic endogenous ligands of certain receptors, making it a candidate for the treatment of neurological and psychiatric diseases. Preclinical studies have shown that this compound can modulate neurotransmitter systems and has potential benefits in treating conditions such as depression, anxiety, and schizophrenia.

Emerging research suggests that this compound may have neuroprotective properties. By interacting with specific receptors in the brain, it can help protect neurons from damage caused by oxidative stress and excitotoxicity. This makes it a potential candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases.

The structural attributes of (6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol also suggest that it has potential anti-inflammatory effects. Studies have shown that it can inhibit the production of proinflammatory cytokines and modulate inflammatory pathways, making it a potential therapeutic agent for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The compound's interactions with neurotransmitter systems have also been explored in the context of pain management. It has demonstrated efficacy in preclinical pain models, suggesting that it could be developed into a new class of analgesics. Its ability to modulate pain pathways without the addictive properties of traditional opioids makes it a promising candidate for further investigation.

Recent studies have shown that (6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol may have beneficial effects on cardiovascular health. By affecting signaling pathways involved in vasodilation and blood pressure regulation, it could be developed as a treatment for hypertension and other cardiovascular diseases.

The future of (6R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol lies in its further exploration through clinical trials and detailed mechanistic studies. The synthesis of analogs and derivatives would expand its use and enhance its therapeutic potential. In addition, understanding its pharmacokinetics and long-term safety profile is essential to developing it as a viable therapeutic agent.

References

none